Advanced Accelerator Applications SA (NASDAQ: AAAP) was founded in 2002 in Bourg-en-Bresse, France. It is headquartered in Saint-Gernes-Buy, France. It has 368 full-time employees (8/31/2015). It is an innovative radiopharmaceutical company engaged in Development, production and commercial application of molecular nuclear medicine products (Molecular Nuclear Medicine, MNM).
Advanced Accelerator Applications (AAAP):
MNM is a medical specialty that uses trace amounts of radioactive compounds to treat diseases such as cancer and create functional images of organs and lesions. Advanced Accelerator Applications’ lead product candidate, Lutathera, is a new type of MNM compound, and the company is currently conducting trials for the treatment of midgut neuroendocrine tumors (NETs), a significant unmet medical need. Lutathera is a kind of Lutetium-177 (or Lu-177), a labeled somatostatin analog peptide, which has been awarded the title of orphan drug by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
Advanced Accelerator Applications (AAAP) investment:
Company’s official website | Market trend
Advanced Accelerator Applications submitted its IPO prospectus on October 1, 2015, and landed on Nasdaq on November 11, 2015, with an issue price of US$16 and a fund-raising of US$75 million, stock code: AAAP.